Background: The impact of radiotherapy (RT) for rectal cancer on ovarian androgen production is unknown. The aim was to examine the effect of RT for rectal cancer on androgen levels in non-oophorectomized women and the association with female sexual desire.
Introduction
Postmenopausal ovaries continue to secrete androgens. Testosterone levels do not change as a consequence of the menopause, but decline slowly with age 1 -3 . In women, serum androgens originate from the ovaries, the adrenal glands and from conversion in peripheral tissues. Serum testosterone is derived by direct synthesis in the ovarian stroma or by conversion of androstenedione in the adrenal. The relative ovarian androstenedione production decreases with age, from 40 per cent in premenopausal to 20 per cent in postmenopausal women. Dehydroepiandrosterone sulphate (DHEA-S), a steroid with limited androgenic effect, is synthesized mainly in the adrenal glands 2, 3 .
Radiotherapy (RT) for rectal cancer induces amenorrhoea and infertility in premenopausal women, but its effect on ovarian androgen production is not known 4, 5 . Evidence for the impact of RT in the treatment of gynaecological cancers on ovarian testosterone production is limited and conflicting 6 -8 . In men, preoperative RT for rectal cancer has a negative impact on serum testosterone levels owing to acute testicular failure related to the cumulative testicular dose 9 . The negative impact on endocrine testicular function might be permanent in selected men, resulting in clinically relevant hypogonadism 10 .
Androgens may play an important role in female sexual function 11 . Serum testosterone levels have been associated with sexual desire and arousal 11 -13 . Experimental and human data suggest a direct impact on libido through androgen receptors in the central nervous system, as well as an effect on the genital physiological response through regulation of smooth muscle and local blood flow 14 -16 . RT is a risk factor for sexual dysfunction after treatment for rectal cancer 17 -19 . Decreased sexual desire is common among women treated for rectal cancer, particularly after RT 20, 21 . A potentially treatable RT-induced decrease in ovarian testosterone production might be a contributing factor. The aim of this study was to examine the effect of RT for rectal cancer on ovarian testosterone production, and to explore the impact on sexual desire in women.
Methods
Patients were recruited from the outpatient clinics of five Swedish rectal cancer surgery centres (Karolinska University Hospital, Ersta Hospital, Örebro University Hospital, Linköping University Hospital and Norrköping Hospital) between June 2008 and August 2013. Follow-up was 1 year. Patient data were collected, questionnaires completed, and fasting venous blood samples were drawn at baseline and 1 year after surgery. Participants who underwent preoperative RT had an additional blood sample taken the day before surgery. Clinical information was recorded on case report forms by a research nurse. The study was approved by the Regional Ethical Review Board in Stockholm (2008/247-31/3, 2012/1730-30/3), and registered at ClinicalTrials.gov (NCT01216189).
Participants
Women aged over 18 years diagnosed with stage I-III rectal cancer planned for abdominal resection were eligible and included after providing informed consent. Exclusion criteria were: previous pelvic RT and inability to provide informed consent owing to linguistic or cognitive restrictions. To define a study population with intact ovarian testosterone production, the present study was restricted to participants without a history of oophorectomy or oophorectomy during surgery for rectal cancer.
Oncological therapy
Preoperative RT was administered as either short-course (5 Gy × 5) or long-course (2 Gy × 25 or 1⋅8 Gy × 25 with or without 3 fractions of boost to the primary tumour and radiologically malignant lymph nodes) treatment. The use and type of preoperative RT given was decided at a multidisciplinary team meeting. The decision to use RT was based on tumour characteristics and cancer stage without knowledge of individual androgen levels. The clinical target volume covered the mesorectum and involved regional lymph node stations, with the upper limit at the level of the bifurcation of the common iliac artery or the sacral promontory. No specific considerations were made to minimize the dose to the ovaries, which are normally exposed to the dose of the planned target volume. The standard chemoradiotherapy regimen comprised capecitabine (825 mg/m 2 twice daily) concomitantly with 50⋅4 Gy RT, followed by surgery and, selectively, eight cycles of adjuvant CAPOX (capecitabine 1000 mg/m 2 on days 1-14 and oxaliplatin 130 mg/m 2 every 3 weeks). A few participants were treated within the phase III RAPIDO (Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation) trial 22 , where participants were randomized to either standard chemoradiotherapy followed by surgery and CAPOX or short-course RT followed by six cycles of neoadjuvant CAPOX and surgery.
Sex hormone levels and sexual desire
The primary outcome was serum testosterone level. Secondary outcomes were calculated free testosterone level, serum levels of androstenedione and DHEA-S, and sexual desire. Serum was separated after centrifugation and stored at -20 ∘ C. All samples were analysed in a single batch. Technical details of the analyses are provided in Appendix S1 (supporting information).
Sexual desire was assessed using the domain score for sexual desire of the Female Sexual Function Index 23 . Scores range from 1⋅2 to 6, with a high score representing high level of sexual desire. A score of 5 or less is proposed as a cut-off value to identify premenopausal women with low sexual desire 24 . Women treated for rectal cancer are usually postmenopausal and older. Therefore, sexual desire scores in the present cohort were expected to be lower than those for premenopausal women. To compare women with high versus low sexual desire in the present study, the scores for sexual desire were dichotomized by a cut-off value of 3 points, which reflects the 75th percentile of the sexual desire score at baseline in women included in this study.
Bias
Participation in the study was not restricted by age, sexual activity or current relationship to reduce the risk of Did not meet inclusion criteria n = 78 Stage IV n = 57 Inability to give informed consent n = 15 Life expectancy < 2 years n = 6
Not included n = 184 Not invited n = 69 Declined to participate n = 40 Surgery at other hospital n = 37 Referred after radiotherapy n = 26 Acute surgery n = 3 Other n = 9
RT -group Analysed at baseline n = 27 RT + group Analysed at baseline n = 98
History of oophorectomy n = 17
Analysed after radiotherapy and before surgery n = 87
Lost to follow-up n = 11
Oophorectomy at time of resection of primary tumour n = 1
Analysed 1 year after surgery n = 66
Lost to follow-up n = 10 Moved from region n = 1 Stage IV n = 2 Unknown reasons n = 7
Analysed 1 year after surgery n = 20
Oophorectomy at time resection of primary tumour n = 11
Lost to follow-up n = 6 Unknown reasons n = 6
Fig. 1 Flow chart for the study. RT-, surgery alone; RT+, preoperative radiotherapy and surgery selection bias. Androgen levels and gynaecological status were unknown at inclusion. Blood samples were collected between 08.00 and 11.00 hours after overnight fasting to avoid information bias owing to hormone level circadian oscillation. To further minimize information bias, serum analyses were undertaken in a single batch. To reduce the negative influence of the recently diagnosed cancer on the baseline sexual function score, patients were asked to answer according to their situation before diagnosis.
Statistical analysis
Stata ® version 14 (StataCorp, College Station, Texas, USA) was used for statistical analysis. Groups were compared using Wilcoxon rank-sum, Wilcoxon matched-pairs signed-rank and Fisher's exact tests as appropriate, with two-sided 5 per cent significance levels.
A generalized estimating equation (GEE) approach was used to analyse the change in androgen levels over time in the groups that did or did not receive RT. This approach gives robust estimates of population averages even with unbalanced data or mis-specified correlation structure. The fitted generalized linear regression models contained linear splines with one knot the day before surgery to account for non-linear trends of change in androgen levels. The applied GEE models had the following specification: gaussian distribution of the dependent variable (androgens), exchangeable within-group correlation structure and conventional variance estimator. The reported coefficients represent the main effect on androgen levels (serum testosterone, free testosterone, serum androstenedione and DHEA-S) over the study period.
The following co-variables were considered as confounders and/or effect modifiers: age, BMI, ASA physical status grade, menopausal status (follicle-stimulating hormone level over 25 units/l was regarded as postmenopausal), oestradiol level, luteinizing hormone level, type of RT, type of surgery (abdominoperineal excision of rectum (APER) versus low anterior resection with temporary ileostomy) and postoperative chemotherapy. Co-variables that changed the unadjusted point estimates by more than 10 per cent and had significant interaction terms were included in the final models.
The association between sexual desire and change in androgen levels was also assessed by GEE models without linear splines, specified by binomial distribution of the dependent variable (high versus low sexual desire), exchangeable within-group correlation structure and conventional variance estimator. The effect of change in androgen levels on sexual desire is reported as an odds ratio comparing the odds of experiencing high versus low sexual desire for a 1-unit increase in androgen level. The final longitudinal regression models were adjusted for confounding and effect modification analogous to the models with androgen levels as outcome, as described above.
Results
Four hundred and four women with rectal cancer were assessed for eligibility, and 142 were included in the study (Fig. 1) . Seventeen who had undergone oophorectomy were excluded, leaving 125 women in the analysis. Baseline characteristics of the study cohort are shown in Table 1 . Ninety-eight women were treated with preoperative RT (RT+ group). Forty-two patients had short-course RT with immediate surgery, 20 with delayed surgery, and one had short-course RT followed by chemotherapy and delayed surgery. Thirty-five patients had long-course RT with delayed surgery, of whom 29 had concomitant chemotherapy. Patients in the RT+ group were younger, more likely to undergo APER and had more severe perioperative events than patients who had surgery alone (RT-group). There were no differences in menopausal status, ASA grade, BMI or pathological tumour stage between groups. The final histology of the tumour in one patient in the RT-group was adenoma, even though it was assessed as adenocarcinoma on histopathological examination of preoperative biopsies. The proportion of patients treated with adjuvant chemotherapy did not differ between the groups.
Twelve women had unilateral or bilateral oophorectomy concomitantly with resection of the primary tumour, and were excluded from analysis 1 year after surgery. Twenty-seven women were lost to follow-up (Fig. 1) .
Androgen levels
Serum levels of androgens are shown in Table 2 and Fig. 2 . Baseline levels of testosterone, free testosterone and androstenedione were similar in the RT+ and RT-groups, whereas median DHEA-S was higher in among women who had RT. In the RT+ group, a significant decline in levels of testosterone, free testosterone, androstenedione and DHEA-S was registered during the first year after surgery. In the RT-group, the decrease was not significant for testosterone, free testosterone and androstenedione, but there was a significant reduction in DHEA-S levels. Cross-sectional comparisons 1 year after surgery showed no significant differences between the RT+ and RTgroups in any of the androgens measured.
The results of adjusted longitudinal regression analysis with linear spline models are shown in Table 3 . There were no significant changes in androgen levels from baseline to 1 year after surgery in the RT-group, whereas among women exposed to preoperative RT there was a decline in testosterone and free testosterone levels. The interactions with time were significant for menopausal status in the testosterone model, for oestrogen in the androstenedione model, and for postoperative chemotherapy and age in the DHEA-S model. No interaction was found in the model for free testosterone.
Response rates regarding sexual desire were 120 of 125 (96⋅0 per cent) at baseline and 86 of 86 (100 per cent) 1 year after surgery. The score for sexual desire did not differ between groups at baseline (P = 0⋅322). The median sexual desire score declined from 2⋅2 (range 1⋅2-6⋅0) to 1⋅8 (1⋅2-5⋅4) in the RT+ group during the first Table 3 Results of longitudinal regression analysis with linear spline models showing adjusted change over time in androgen levels from baseline to 1 year after surgery
Main effect over time in serum levels of androgens P
Values in parentheses are 95 per cent confidence intervals. Adjusted for *menopausal status, †serum luteinizing hormone and serum oestradiol (interaction), ‡postoperative chemotherapy (interaction), preoperative radiotherapy and age (interaction). RT-, surgery alone; RT+, preoperative radiotherapy and surgery; DHEA-S, dehydroepiandrosterone sulphate.
year after surgery (P = 0⋅016), but did not change in the RT-group (1⋅8 (1⋅2-4⋅2) and 1⋅8 (1⋅2-4⋅8) respectively; P = 0⋅571). The adjusted longitudinal regression analysis Table 4 Results of longitudinal regression analysis of the association between mean change in androgen levels and change in sexual desire
Values in parentheses are 95 per cent confidence intervals. Scores for sexual desire were dichotomized on the 75th percentile at baseline. The odds ratio signifies the probability of reporting sexual desire above the 75th percentile if the androgen level increases by 1 unit. *Adjusted for follicle-stimulating hormone (FSH); †adjusted for FSH and BMI; ‡interaction with FSH and adjusted for BMI. DHEA-S, dehydroepiandrosterone sulphate.
showed an association between sexual desire and mean change in testosterone, free testosterone, androstenedione and DHEA-S levels ( Table 4) .
Discussion
In this prospective cohort study, RT was associated with a decrease in levels of androgens of ovarian origin (testosterone and free testosterone). No association was observed between RT and androgens produced mainly in the adrenals (androstenedione and DHEA-S). The change in testosterone, free testosterone and androstenedione levels was associated with a decline in sexual desire. The effect of RT for rectal cancer and reduction in ovarian androgen levels has not been described previously. The effect of RT on testosterone levels after cervical cancer has been examined in three smaller studies 6 -8 , which reported divergent results. The ovarian stroma, where testosterone synthesis takes place, may be more resistant to RT than the oestrogen-producing follicular tissue 8 . A possible mechanism underlying the observed association between RT and testosterone reduction could be slow fibrosis and vascular injury that negatively affect the androgen-producing stromal cells. Fibrosis development over time may explain why no significant decline in serum testosterone and free testosterone levels was seen shortly after RT.
The reported levels of testosterone at baseline and 1 year after surgery in both the RT+ and RT-groups are within the normal range for postmenopausal women, and their clinical relevance is not clear. In this cohort, levels of serum testosterone, free testosterone and androstenedione were positively associated with sexual desire. Sexual interest and desire have been reported to decline with low testosterone levels in women 12, 13, 25 . Reference androgen levels with associations to specific symptoms are not available, and there is no lower limit of endogenous androgens to identify women with sexual dysfunction. Several randomized trials of exogenous testosterone treatment have reported improved sexual desire, arousal and other aspects of female sexual function in naturally and surgically postmenopausal women with hypoactive sexual desire disorder 26, 27 . Sexual dysfunction has been well described after treatment for rectal cancer, with RT as a clear risk factor 17, 19, 21, 28 .
Treatment decisions about preoperative RT use were made at multidisciplinary treatment conferences, based on staging and general health, without knowledge of androgen levels. The lower age of women in the RT+ group is not surprising as multimodal treatment for rectal cancer is more frequently used in younger patients with limited co-morbidity. Ovarian androgen production does not decline in the same manner as oestrogen production at menopause, and age did not relevantly change the longitudinal models for testosterone, free testosterone and androstenedione in this study. Women with potentially intact ovarian androgen production were assessed here to define a study population at risk. The baseline ovarian androgen levels in the two groups were similar, even though participants in the RT-group were older. The high frequency of APER in the cohort reflects the rectal cancer population treated at tertiary referral centres with a high proportion of locally advanced and low rectal cancers. In this study, 21⋅6 per cent of patients were lost to follow-up, but the association between RT and decrease in testosterone is not expected to be different from that for included patients.
Liquid chromatography tandem mass spectrometry, the most accurate method for measurement of serum total testosterone 29 , was used in this study. Free testosterone was calculated using a new multistep dynamic model 30 . This model is more accurate than Vermeulen's model, as the systematic error in calculated free testosterone values in women is reduced significantly.
The longitudinal regression models were adjusted for age, BMI, ASA grade, menopausal status, oestradiol level, luteinizing hormone level, type of RT, type of surgery (anterior resection with anastomosis or APER) and postoperative chemotherapy if models containing the co-variables above indicated relevant confounding or effect modulation. It is not known whether treatment with oxaliplatin and fluorouracil has an impact on ovarian androgen production. Observational studies 5, 31 have indicated a moderate transient (less than 6 months) gonadotoxic effect of oxaliplatin in premenopausal women. Fluorouracil is considered to have almost no effect on human reproductive function.
Preoperative RT for rectal cancer was associated with a decrease in testosterone and free testosterone of mainly ovarian origin, which was not the case for androstenedione and DHEA-S, androgens of mainly adrenal origin. These results indicate that RT has a negative impact on ovarian androgen-producing stromal cells. The decrease in testosterone and free testosterone levels was observed up to the first year after surgery for rectal cancer, which raises concerns about a permanent adverse effect of RT. The clinical relevance of the decline in androgens warrants further exploration. Possible adverse effects from decreased testosterone levels include negative effects on body composition, sarcopenia and bone turnover 3 . The present study suggests that androgens of ovarian origin are related to sexual desire. Reduced sexual desire is a common complaint in women treated for rectal cancer. This possible link between a decline in androgen levels and sexual desire could be taken into account during the preoperative information and rehabilitation process as testosterone replacement therapy may be considered in women.
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